News

PMLive12m
Novartis to expand renal disease pipeline with $1.7bn Regulus acquisition
Novartis has announced that it will be acquiring Regulus Therapeutics in a deal worth $1.7bn, marking a notable boost to the ...
PMLive13m
FDA approves Abeona’s epidermolysis bullosa gene therapy Zevaskyn
The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) for use in ...